MAPT and Alzheimer disease: We found similar results when we measured endogenous mouse tau levels: both 3xTg‐AD groups had significantly higher tau5 levels than the two NonTg groups (P < 0.0001), while the treatment did not alter total tau levels (Fig. 2A,C).